Hardware, Equipment & Parts
Compare Stocks
5 / 10Stock Comparison
MLAB vs TRMB vs NOVT vs OSIS vs MKSI
Revenue, margins, valuation, and 5-year total return — side by side.
Hardware, Equipment & Parts
Hardware, Equipment & Parts
Hardware, Equipment & Parts
Hardware, Equipment & Parts
MLAB vs TRMB vs NOVT vs OSIS vs MKSI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Hardware, Equipment & Parts | Hardware, Equipment & Parts | Hardware, Equipment & Parts | Hardware, Equipment & Parts | Hardware, Equipment & Parts |
| Market Cap | $578M | $14.40B | $4.93B | $3.80B | $21.09B |
| Revenue (TTM) | $248M | $3.69B | $981M | $1.81B | $4.07B |
| Net Income (TTM) | $4M | $456M | $54M | $152M | $327M |
| Gross Margin | 60.6% | 68.1% | 44.4% | 32.8% | 45.2% |
| Operating Margin | 7.0% | 17.8% | 11.9% | 12.1% | 14.8% |
| Forward P/E | 11.5x | 19.7x | 38.8x | 22.1x | 27.3x |
| Total Debt | $181M | $1.39B | $342M | $682M | $4.69B |
| Cash & Equiv. | $27M | $253M | $381M | $106M | $675M |
MLAB vs TRMB vs NOVT vs OSIS vs MKSI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Mesa Laboratories, … (MLAB) | 100 | 39.6 | -60.4% |
| Trimble Inc. (TRMB) | 100 | 155.4 | +55.4% |
| Novanta Inc. (NOVT) | 100 | 134.7 | +34.7% |
| OSI Systems, Inc. (OSIS) | 100 | 304.2 | +204.2% |
| MKS Inc. (MKSI) | 100 | 296.5 | +196.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MLAB vs TRMB vs NOVT vs OSIS vs MKSI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MLAB carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 1.75, yield 0.6%
- Rev growth 11.5%, EPS growth 99.2%, 3Y rev CAGR 9.3%
- Beta 1.75, yield 0.6%, current ratio 0.63x
- 11.5% revenue growth vs TRMB's -2.6%
TRMB is the #2 pick in this set and the best alternative if sleep-well-at-night is your priority.
- Lower volatility, beta 1.35, Low D/E 23.9%, current ratio 1.09x
- 12.4% margin vs MLAB's 1.5%
- Beta 1.35 vs MKSI's 2.56, lower leverage
NOVT is the clearest fit if your priority is long-term compounding.
- 8.7% 10Y total return vs MKSI's 7.8%
OSIS ranks third and is worth considering specifically for valuation efficiency.
- PEG 1.34 vs NOVT's 11.78
- 6.3% ROA vs MLAB's 0.9%, ROIC 11.5% vs 3.7%
MKSI is the clearest fit if your priority is momentum.
- +306.4% vs MLAB's -16.1%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 11.5% revenue growth vs TRMB's -2.6% | |
| Value | Lower P/E (11.5x vs 27.3x) | |
| Quality / Margins | 12.4% margin vs MLAB's 1.5% | |
| Stability / Safety | Beta 1.35 vs MKSI's 2.56, lower leverage | |
| Dividends | 0.6% yield, vs MKSI's 0.3%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +306.4% vs MLAB's -16.1% | |
| Efficiency (ROA) | 6.3% ROA vs MLAB's 0.9%, ROIC 11.5% vs 3.7% |
MLAB vs TRMB vs NOVT vs OSIS vs MKSI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
MLAB vs TRMB vs NOVT vs OSIS vs MKSI — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
TRMB leads in 1 of 6 categories
OSIS leads 1 • MKSI leads 1 • MLAB leads 1 • NOVT leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
TRMB leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MKSI is the larger business by revenue, generating $4.1B annually — 16.4x MLAB's $248M. TRMB is the more profitable business, keeping 12.4% of every revenue dollar as net income compared to MLAB's 1.5%. On growth, MKSI holds the edge at +15.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $248M | $3.7B | $981M | $1.8B | $4.1B |
| EBITDAEarnings before interest/tax | $37M | $843M | $179M | $229M | $945M |
| Net IncomeAfter-tax profit | $4M | $456M | $54M | $152M | $327M |
| Free Cash FlowCash after capex | $38M | $253M | $48M | $77M | $401M |
| Gross MarginGross profit ÷ Revenue | +60.6% | +68.1% | +44.4% | +32.8% | +45.2% |
| Operating MarginEBIT ÷ Revenue | +7.0% | +17.8% | +11.9% | +12.1% | +14.8% |
| Net MarginNet income ÷ Revenue | +1.5% | +12.4% | +5.5% | +8.4% | +8.0% |
| FCF MarginFCF ÷ Revenue | +15.2% | +6.9% | +4.9% | +4.2% | +9.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.6% | +11.8% | +8.5% | +2.0% | +15.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +3.1% | +55.6% | -2.2% | -3.8% | +53.2% |
Valuation Metrics
Evenly matched — MLAB and OSIS each lead in 3 of 7 comparable metrics.
Valuation Metrics
At 26.5x trailing earnings, OSIS trades at a 72% valuation discount to NOVT's 94.1x P/E. Adjusting for growth (PEG ratio), OSIS offers better value at 1.60x vs NOVT's 28.55x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $578M | $14.4B | $4.9B | $3.8B | $21.1B |
| Enterprise ValueMkt cap + debt − cash | $732M | $15.5B | $4.9B | $4.4B | $25.1B |
| Trailing P/EPrice ÷ TTM EPS | -290.69x | 34.73x | 94.09x | 26.47x | 71.67x |
| Forward P/EPrice ÷ next-FY EPS est. | 11.54x | 19.67x | 38.82x | 22.13x | 27.27x |
| PEG RatioP/E ÷ EPS growth rate | — | 14.14x | 28.55x | 1.60x | — |
| EV / EBITDAEnterprise value multiple | 17.92x | 19.73x | 27.40x | 16.76x | 27.62x |
| Price / SalesMarket cap ÷ Revenue | 2.40x | 4.01x | 5.03x | 2.22x | 5.36x |
| Price / BookPrice ÷ Book value/share | 3.55x | 2.50x | 3.86x | 4.16x | 7.80x |
| Price / FCFMarket cap ÷ FCF | 13.67x | 108.10x | 101.87x | 67.74x | 42.43x |
Profitability & Efficiency
OSIS leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
OSIS delivers a 16.7% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $2 for MLAB. TRMB carries lower financial leverage with a 0.24x debt-to-equity ratio, signaling a more conservative balance sheet compared to MKSI's 1.73x. On the Piotroski fundamental quality scale (0–9), MLAB scores 6/9 vs OSIS's 4/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +2.0% | +8.0% | +4.1% | +16.7% | +12.2% |
| ROA (TTM)Return on assets | +0.9% | +5.0% | +3.0% | +6.3% | +3.7% |
| ROICReturn on invested capital | +3.7% | +6.8% | +7.4% | +11.5% | +6.5% |
| ROCEReturn on capital employed | +4.9% | +7.8% | +8.3% | +16.3% | +7.2% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 | 5 | 4 | 6 |
| Debt / EquityFinancial leverage | 1.14x | 0.24x | 0.26x | 0.72x | 1.73x |
| Net DebtTotal debt minus cash | $154M | $1.1B | -$39M | $576M | $4.0B |
| Cash & Equiv.Liquid assets | $27M | $253M | $381M | $106M | $675M |
| Total DebtShort + long-term debt | $181M | $1.4B | $342M | $682M | $4.7B |
| Interest CoverageEBIT ÷ Interest expense | 2.36x | 8.03x | 4.89x | 11.43x | 2.84x |
Total Returns (Dividends Reinvested)
MKSI leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in OSIS five years ago would be worth $24,066 today (with dividends reinvested), compared to $4,335 for MLAB. Over the past 12 months, MKSI leads with a +306.4% total return vs MLAB's -16.1%. The 3-year compound annual growth rate (CAGR) favors MKSI at 56.2% vs MLAB's -12.9% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +32.0% | -22.4% | +24.4% | -9.8% | +86.2% |
| 1-Year ReturnPast 12 months | -16.1% | -9.8% | +13.5% | +3.8% | +306.4% |
| 3-Year ReturnCumulative with dividends | -33.9% | +27.8% | -13.9% | +94.9% | +281.0% |
| 5-Year ReturnCumulative with dividends | -56.7% | -21.8% | +10.3% | +140.7% | +82.1% |
| 10-Year ReturnCumulative with dividends | +3.1% | +162.2% | +867.9% | +352.2% | +784.8% |
| CAGR (3Y)Annualised 3-year return | -12.9% | +8.5% | -4.9% | +24.9% | +56.2% |
Risk & Volatility
Evenly matched — TRMB and MKSI each lead in 1 of 2 comparable metrics.
Risk & Volatility
TRMB is the less volatile stock with a 1.35 beta — it tends to amplify market swings less than MKSI's 2.56 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MKSI currently trades 95.8% from its 52-week high vs TRMB's 69.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.75x | 1.35x | 2.07x | 1.36x | 2.56x |
| 52-Week HighHighest price in past year | $131.20 | $87.50 | $149.95 | $311.27 | $326.83 |
| 52-Week LowLowest price in past year | $55.45 | $59.84 | $98.27 | $204.00 | $73.21 |
| % of 52W HighCurrent price vs 52-week peak | +79.8% | +69.5% | +92.2% | +74.1% | +95.8% |
| RSI (14)Momentum oscillator 0–100 | 66.3 | 33.0 | 58.9 | 30.6 | 68.0 |
| Avg Volume (50D)Average daily shares traded | 125K | 1.8M | 377K | 288K | 1.2M |
Analyst Outlook
MLAB leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: MLAB as "Hold", TRMB as "Buy", NOVT as "Buy", OSIS as "Buy", MKSI as "Buy". Consensus price targets imply 53.8% upside for TRMB (target: $94) vs -10.2% for MLAB (target: $94). For income investors, MLAB offers the higher dividend yield at 0.61% vs MKSI's 0.28%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $94.00 | $93.50 | $150.00 | $301.00 | $294.25 |
| # AnalystsCovering analysts | 8 | 28 | 3 | 17 | 29 |
| Dividend YieldAnnual dividend ÷ price | +0.6% | — | — | — | +0.3% |
| Dividend StreakConsecutive years of raises | 0 | — | — | — | 0 |
| Dividend / ShareAnnual DPS | $0.64 | — | — | — | $0.87 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +6.0% | +0.8% | +2.1% | +0.2% |
TRMB leads in 1 of 6 categories (Income & Cash Flow). OSIS leads in 1 (Profitability & Efficiency). 2 tied.
MLAB vs TRMB vs NOVT vs OSIS vs MKSI: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is MLAB or TRMB or NOVT or OSIS or MKSI a better buy right now?
For growth investors, Mesa Laboratories, Inc.
(MLAB) is the stronger pick with 11. 5% revenue growth year-over-year, versus -2. 6% for Trimble Inc. (TRMB). OSI Systems, Inc. (OSIS) offers the better valuation at 26. 5x trailing P/E (22. 1x forward), making it the more compelling value choice. Analysts rate Trimble Inc. (TRMB) a "Buy" — based on 28 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MLAB or TRMB or NOVT or OSIS or MKSI?
On trailing P/E, OSI Systems, Inc.
(OSIS) is the cheapest at 26. 5x versus Novanta Inc. at 94. 1x. On forward P/E, Mesa Laboratories, Inc. is actually cheaper at 11. 5x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: OSI Systems, Inc. wins at 1. 34x versus Novanta Inc. 's 11. 78x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — MLAB or TRMB or NOVT or OSIS or MKSI?
Over the past 5 years, OSI Systems, Inc.
(OSIS) delivered a total return of +140. 7%, compared to -56. 7% for Mesa Laboratories, Inc. (MLAB). Over 10 years, the gap is even starker: NOVT returned +867. 9% versus MLAB's +3. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MLAB or TRMB or NOVT or OSIS or MKSI?
By beta (market sensitivity over 5 years), Trimble Inc.
(TRMB) is the lower-risk stock at 1. 35β versus MKS Inc. 's 2. 56β — meaning MKSI is approximately 89% more volatile than TRMB relative to the S&P 500. On balance sheet safety, Trimble Inc. (TRMB) carries a lower debt/equity ratio of 24% versus 173% for MKS Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — MLAB or TRMB or NOVT or OSIS or MKSI?
By revenue growth (latest reported year), Mesa Laboratories, Inc.
(MLAB) is pulling ahead at 11. 5% versus -2. 6% for Trimble Inc. (TRMB). On earnings-per-share growth, the picture is similar: Mesa Laboratories, Inc. grew EPS 99. 2% year-over-year, compared to -71. 3% for Trimble Inc.. Over a 3-year CAGR, OSIS leads at 13. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MLAB or TRMB or NOVT or OSIS or MKSI?
Trimble Inc.
(TRMB) is the more profitable company, earning 11. 8% net margin versus -0. 8% for Mesa Laboratories, Inc. — meaning it keeps 11. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TRMB leads at 16. 9% versus 6. 8% for MLAB. At the gross margin level — before operating expenses — TRMB leads at 68. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MLAB or TRMB or NOVT or OSIS or MKSI more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, OSI Systems, Inc. (OSIS) is the more undervalued stock at a PEG of 1. 34x versus Novanta Inc. 's 11. 78x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Mesa Laboratories, Inc. (MLAB) trades at 11. 5x forward P/E versus 38. 8x for Novanta Inc. — 27. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TRMB: 53. 8% to $93. 50.
08Which pays a better dividend — MLAB or TRMB or NOVT or OSIS or MKSI?
In this comparison, MLAB (0.
6% yield), MKSI (0. 3% yield) pay a dividend. TRMB, NOVT, OSIS do not pay a meaningful dividend and should not be held primarily for income.
09Is MLAB or TRMB or NOVT or OSIS or MKSI better for a retirement portfolio?
For long-horizon retirement investors, OSI Systems, Inc.
(OSIS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+352. 2% 10Y return). MKS Inc. (MKSI) carries a higher beta of 2. 56 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OSIS: +352. 2%, MKSI: +784. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MLAB and TRMB and NOVT and OSIS and MKSI?
Both stocks operate in the Technology sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
MLAB pays a dividend while TRMB, NOVT, OSIS, MKSI do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.